Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 7/20 | 0.37 |
| ▸ | PPARG | P37231 | 7/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477285 | 0.94 | PDE7A (0.37) | AGTR1PPARGMAPTCYP1A2CYP2C19 | |
| SCHEMBL4487077 | 0.94 | PDE7A (0.37) | AGTR1PPARGMAPTCYP1A2CYP2C19 | |
| SCHEMBL4480752 | 0.94 | PDE7A (0.37) | AGTR1PPARGMAPTCYP1A2CYP2C19 | |
| SCHEMBL4478347 | 0.87 | CMA1 (0.36) | AGTR1PPARGAPLNRMAPTCMA1 | |
| SCHEMBL4478355 | 0.87 | CMA1 (0.36) | AGTR1PPARGAPLNRMAPTCMA1 | |
| SCHEMBL4471445 | 0.85 | ALDH1A1 (0.38) | AGTR1PPARGAPLNRSMN1; SMN2CMA1 | |
| SCHEMBL4465216 | 0.83 | MAPT (0.37) | MAPTCYP1A2CYP2C19SMN1; SMN2ALDH1A1 | |
| SCHEMBL4478024 | 0.82 | PDE7A (0.36) | MAPTSMN1; SMN2CMA1MAOBALDH1A1 | |
| SCHEMBL4479225 | 0.82 | PDE7A (0.36) | MAPTSMN1; SMN2CMA1MAOBALDH1A1 | |
| SCHEMBL4479230 | 0.82 | PDE7A (0.36) | MAPTSMN1; SMN2CMA1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582651-B2 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1535922-A1 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167038-A1 | Pyrrolopyridine derivative and use thereof | OPRD1, TRPV1, OPRM1 | AGTR1 227/4885PPARG 1174/4885APLNR 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.